BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramanathan RK. Alternative dosing schedules for cetuximab: a role for biweekly administration? Clin Colorectal Cancer 2008;7:364-8. [PMID: 19036688 DOI: 10.3816/CCC.2008.n.048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Schoennemann KR, Bjerregaard JK, Hansen TP, De Stricker K, Gjerstorff MF, Jensen HA, Vestermark LW, Pfeiffer P. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer. 2011;14:219-225. [PMID: 21409520 DOI: 10.1007/s10120-011-0031-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
2 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
3 Kersten C, Cameron MG. Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Rep 2012;2012:bcr1220115374. [PMID: 22707700 DOI: 10.1136/bcr.12.2011.5374] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]